What is Entact Bio?
Entact Bio operates at the intersection of advanced molecular biology and drug discovery, specializing in the development of targeted small molecules known as ENTACs. Unlike conventional pharmaceutical approaches that often focus on protein degradation or inhibition, Entact Bio leverages its Encompass platform to restore, relocate, or amplify protein activity within the cellular environment. This unique mechanism of action allows the company to tackle a broad spectrum of diseases that have historically been considered beyond the reach of standard pharmacological intervention. By optimizing the natural capabilities of proteins, the firm is building a robust pipeline aimed at addressing high-unmet-need conditions, thereby establishing a significant competitive advantage in the biotechnology sector.
How much funding has Entact Bio raised?
Entact Bio has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2026): $10M, investors not publicly disclosed
Key Investors in Entact Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Entact Bio?
With this major enterprise-level funding, Entact Bio is poised to accelerate the clinical validation of its lead candidates and expand the reach of its Encompass platform. The strategic roadmap likely involves scaling internal research capabilities to broaden the scope of ENTAC applications across diverse therapeutic areas, including oncology and rare genetic diseases. As the company transitions from early-stage discovery to more advanced development phases, the focus will shift toward establishing strategic partnerships and optimizing manufacturing processes for its novel small molecule therapeutics. Investors will be closely monitoring the firm's ability to translate its protein-enhancement methodology into tangible clinical outcomes, which will be the primary driver for future valuation growth and long-term market sustainability.
See full Entact Bio company page
